Skip to main content

Table 2 Pharmacokinetic parameters

From: Bioequivalence study of three ibuprofen formulations after single dose administration in healthy volunteers

Parameter analyzed

Sequence

Treatment

Mean

SD

CV (%)

Geometric mean

AUC0-t(last) (μg/ml*h)

AE/EA

Nurofen®

117.00

31.94

27.3

113.4

  

Eudorlin®

119.79

29.04

24.2

116.6

 

EB/BE

Migränin®

115.21

21.83

19.0

113.1

  

Eudorlin®

115.84

22.73

19.6

113.7

AUC0-∞ (μg/ml*h)

AE/EA

Nurofen®

117.38

32.01

27.3

113.8

  

Eudorlin®

120.15

29.07

24.2

117.0

 

EB/BE

Migränin®

115.57

21.84

18.9

113.5

  

Eudorlin®

116.22

22.73

19.6

114.1

Cmax (μg/ml)

AE/EA

Nurofen®

32.92

8.29

25.2

31.83

  

Eudorlin®

36.62

6.16

16.8

36.11

 

EB/BE

Migränin®

30.87

6.31

20.4

30.25

  

Eudorlin®

35.94

6.30

17.5

35.41

t1/2 (h)

AE/EA

Nurofen®

2.52

0.44

17.6

2.495

  

Eudorlin®

2.55

0.42

16.6

2.522

 

EB/BE

Migränin®

2.50

0.33

13.1

2.478

  

Eudorlin®

2.66

0.79

29.8

2.583

   

Mean

SD

CV

Median

tmax (h)

AE/EA

Nurofen®

1.82

1.05

57.9

1.50

  

Eudorlin®

1.14

0.67

59.1

1.00

 

EB/BE

Migränin®

1.78

0.97

54.5

1.75

  

Eudorlin®

1.13

0.80

71.1

0.75

  1. Pharmacokinetic data by treatment pair and treatment (Pharmacokinetic population; N = 60). "A" refers to Nurofen® forte, "B" refers to Migränin® and "E" refers to Eudorlin® extra. SD: standard deviation, CV: coefficient of variation.